ÇÁ·Î±×·¥

Çѱ¹ÀÀ¿ë¾à¹°ÇÐȸ ½Å¾à°³¹ßÀü¹®°¡ ¾ç¼º ±³À° ÇÁ·Î±×·¥: ½ÉÈ­°úÁ¤

»çȸ: ÃÖ¿µÈñ ±³¼ö (µ¿±¹´ëÇб³)

2023³â 11¿ù 3ÀÏ(±Ý)

Time Program
10:00~10:10 Opening Remark
Session 1: Recent Issues for New Drug Development & Drug-Drug Interaction
10:10~10:55 FDAÀÇ ¾à¹° ¾ÈÀü¼º°ú À¯È¿¼º ½É»ç°úÁ¤¿¡¼­ RWD/RWEÀÇ È°¿ë
(Utilizing Real-World Data and Real-World Evidence in FDA Safety and Efficacy Reviews)
¢º Á¤ÅÂÇö ¹Ú»ç (¹Ì±¹ FDA, CDER)
10:55~11:10 Q & A
11:10~11:55 ¾àµ¿ÇÐÀû ¾à¹°»óÈ£ÀÛ¿ëÀÇ ÀÌÇØ
(Understanding pharmacokinetic drug-drug interaction)
¢º ±è¼ÒÈñ ±³¼ö (¾ÆÁÖ´ëÇб³ ¾àÇдëÇÐ)
11:55~12:10 Q & A
12:10~13:30 Lunch
Session 2: Considerations in the Non-clinical Pharmacokinetic Studies
13:30~14:15 In vitro ¾à¹°´ë»ç ¿¬±¸ ¹æ¹ý·Ð ¹× µ¥ÀÌÅÍ ÇØ¼®
(Methodology and Interpretation of In Vitro Metabolism of a Drug)
¢º ÃÖ¿µÈñ ±³¼ö (µ¿±¹´ëÇб³ ¾àÇдëÇÐ)
14:15~14:30 Q & A
14:30~15:15 IVIVE¸¦ ÀÌ¿ëÇÑ °£´ë»ç ¿¹Ãø
(Estimation of in vitro metabolism and in vivo extrapolation)
¢º ±èÀ¯Ã¶ ±³¼ö (ÀÎÁ¦´ëÇб³ Á¦¾à°øÇаú)
15:15~15:30 Q & A
15:30~15:40 Intermediate Break
Session 3: Practical Strategy for New Drug Development
15:40~16:25 Èĺ¸¹°ÁúÃÖÀûÈ­ ¹× ÀÓ»óÁ¦Ãâ¿ë µ¶¼º½ÃÇè
(From Lead Optimization to Global IND-enabling Toxicology)
¢º ±è¼öÇå ´ëÇ¥ (Å¥º£½ºÆ®¹ÙÀÌ¿À)
16:25~16:40 Q & A
16:40~17:25 ºñÀÓ»ó ½Å¾à°³¹ß½Ã °í·Á»çÇ×: IND ¹× ÀÓ»ó½ÃÇè ¼³°è
(Considerations for IND and Clinical Trial Design)
¢º ±è°æ¼ø ±³¼ö (ÀÎÁ¦´ëÇб³ Á¦¾à°øÇаú)
17:25~17:40 Q & A
17:40~ Closing Remark